Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thaw Poon

Internal Medicine Baltimore, MD Medical Doctor

NPI 1912944349 CMS profile 86327

301 Saint Paul Pl, Phys Office Bldg., Suite 701, Baltimore, MD 21202

Open in the dashboard

General payments

$4,166

202 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thaw Poon of Baltimore, MD is reported in the CMS Open Payments database as having received $4,166 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $124 7
2024 General $812 44
2023 General $768 43
2022 General $307 17
2021 General $320 3
2020 General $202 12
2019 General $1,634 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thaw Poon
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thaw Poon were reported at $124. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thaw Poon Internal Medicine median Middle half National median
2019 $1,634 $159 $48–$570 $163
2020 $202 $119 $33–$402 $114
2021 $320 $135 $37–$521 $132
2022 $307 $141 $42–$496 $149
2023 $768 $149 $45–$519 $160
2024 $812 $154 $47–$537 $164
2025 $124 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $726 37 payments
  2. AstraZeneca Pharmaceuticals LP $609 31 payments
  3. AbbVie, Inc. $582 30 payments
  4. Lilly USA, LLC $504 36 payments
  5. E.R. Squibb & Sons, L.L.C. $361 18 payments
  6. Spineology Inc. $211 2 payments
  7. Pfizer Inc. $197 13 payments
  8. Amgen Inc. $182 3 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $143 8 payments
  10. Horizon Therapeutics plc $122 1 payment
  11. Other $528 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,114 199 payments
  2. Education $52 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $506 25 payments
  2. Ozempic $491 31 payments
  3. UBRELVY $440 23 payments
  4. RYBELSUS $306 18 payments
  5. TRULICITY $224 18 payments
  6. QULIPTA $217 9 payments
  7. Tresiba $204 5 payments
  8. BASAGLAR $198 16 payments
  9. NURTEC ODT $197 13 payments
  10. ELIQUIS $192 10 payments
  11. Other $2,787 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 190 drugs

Part D claims

12,781

Median for Internal Medicine: 777

Drug cost

$1,450,907

Median for Internal Medicine: $73,373

Branded share of claims

25.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 175 $221,250
Eliquis Apixaban Brand 227 $216,422
Januvia Sitagliptin Phosphate Brand 115 $123,102
Trulicity Dulaglutide Brand 43 $94,181
Orencia Abatacept Brand 12 $75,180
Xarelto Rivaroxaban Brand 75 $66,564
Jardiance Empagliflozin Brand 46 $55,609
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 161 $48,349
Linzess Linaclotide Brand 61 $41,521
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 59 $41,146

The 10 drugs with the highest cost, of 190 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$204,911

Of which drugs: $17,957

Medicare patients

612

Average age 73

Services billed

3,624

329 women, 283 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 36%
Arthritis 36%
Ischemic heart disease 22%
COPD 18%
Chronic kidney disease 17%
Depression 17%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 195 196 $16,037
Influenza vaccine, trivalent derived from cell cultures 90661 Office 26 26 $939

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $90
$90 — —
RYBELSUS
  • Novo Nordisk Inc $80
$80 — —
Ozempic
  • Novo Nordisk Inc $80
$80 175 —
NURTEC ODT
  • PFIZER INC. $80
$80 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $37
  • PFIZER INC. $34
$71 227 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record